glp-1 obesity drugs - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,840 +0.84%

DJIA 48,336 +0.89%

Nasdaq 25,093 +0.80%

DAX 23,932 -0.13%

Gold $4,196 +0.16%

Oil $95.59 -1.13%

BTC $72,398 +1.44%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

S&P 500 6,840 +0.84%

DJIA 48,336 +0.89%

Nasdaq 25,093 +0.80%

DAX 23,932 -0.13%

Gold $4,196 +0.16%

Oil $95.59 -1.13%

BTC $72,398 +1.44%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

glp-1 obesity drugs

Novo Nordisk Wegovy Strategy illustrated with GLP-1 injection pen and obesity pill on clinical desk

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy Boom With HD Dose Push

By Maik Kemper • Apr 7, 2026

Novo Nordisk Wegovy Strategy products Wegovy pen and pill highlighted against dark background

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide

By Maik Kemper • Mar 31, 2026

Novo Nordisk Wegovy Strategy illustrated with GLP-1 injection pen and obesity pill on clinical desk

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy Boom With HD Dose Push

By Maik Kemper • Apr 7, 2026

Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief…

Novo Nordisk Wegovy Strategy products Wegovy pen and pill highlighted against dark background

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide

By Maik Kemper • Mar 31, 2026

Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to Eli Lilly? Maik Kemper Editor…